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Background: Chloroquine (CQ), a cost effective antimalarial drug with a relatively good safety profile and
therapeutic index, is no longer used by itself to treat patients with Plasmodium falciparum due to CQ-resistant
strains. P. vivax, representing over 90% of malaria cases in Brazil, despite reported resistance, is treated with CQ as
well as with primaquine to block malaria transmission and avoid late P. vivax malaria relapses. Resistance to CQ and
other antimalarial drugs influences malaria control, thus monitoring resistance phenotype by parasite genotyping is
helpful in endemic areas.
Methods: A total of 47 P. vivax and nine P. falciparum fresh isolates were genetically characterized and tested for
CQ, mefloquine (MQ) and artesunate (ART) susceptibility in vitro. The genes mdr1 and pfcrt, likely related to CQ
resistance, were analyzed in all isolates. Drug susceptibility was determined using short-term parasite cultures of ring
stages for 48 to 72 hour and thick blood smears counts. Each parasite isolate was tested with the antimalarials to
measure the geometric mean of 50% inhibitory concentration.
Results: The low numbers of P. falciparum isolates reflect the species prevalence in Brazil; most displayed low
sensitivity to CQ (IC50 70 nM). However, CQ resistance was rare among P. vivax isolates (IC50 of 32 nM). The majority
of P. vivax and P. falciparum isolates were sensitive to ART and MQ. One hundred percent of P. falciparum isolates
carried non-synonymous mutations in the pfmdr1 gene in codons 184, 1042 and 1246, 84% in codons 1034 and
none in codon 86, a well-known resistance mutation. For the pfcrt gene, mutations were observed in codons 72
and 76 in all P. falciparum isolates. One P. falciparum isolate from Angola, Africa, showing sensitivity to the
antimalarials, presented no mutations. In P. vivax, mutations of pvmdr1 and the multidrug resistance gene 1 marker
at codon F976 were absent.
Conclusion: All P. falciparum Brazilian isolates showed CQ resistance and presented non-synonymous mutations in
pfmdr1 and pfcrt. CQ resistant genotypes were not present among P. vivax isolates and the IC50 values were low in
all samples of the Brazilian West Amazon.
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Malaria, one of the most prevalent parasitic diseases in the
world, still causes high morbidity and death, mainly in
Plasmodium falciparum-infected, non-treated patients
[1]. Plasmodium vivax causes intense morbidity and
contributes to significant political, social and economic in-
stability in developing countries of Latin America and Asia
[2,3]. CQ is the drug of choice to treat vivax malaria in en-
demic areas of Brazil and primaquine (PQ) is used to avoid
late malaria relapses [3]. The recommended dose for adults
is 1500 mg of CQ (daily for three days) and 210 mg of PQ
(daily for seven days) [4]. Plasmodium vivax resistance is
now widespread and has rendered CQ ineffective in parts of
Indonesia and Papua New Guinea [5-7]. Low levels of resist-
ance have also been reported in Myanmar, South Korea,
Vietnam, India, Turkey, Ethiopia, and in regions of Southern
Africa and South America [3,8,9]. The occurrence of severe
vivax malaria and patient’s deaths has been reported in
Brazil [10-12] raising the possibility of an association be-
tween malaria severity and drug resistance [13]. In areas
of CQ resistance, treatment of uncomplicated P. falcip-
arum malaria is carried out with artemisinin-based
combination therapy (ACT) [3]. Drugs that comple-
ment ACT include lumefantrine, amodiaquine, AQ, MQ,
sulphadoxine-pyrimethamine and antibiotics. In Brazil, the
first option for falciparum malaria treatment is the combin-
ation of artemether (480 mg daily for four days) and lume-
fantrine (2880 mg daily for four days). PQ (45 mg) is
administrated on day one to avoid malaria transmission.
These doses are recommended for adults with 50 Kg weight
or more [4]. A reduced susceptibility to artemisinin derivatives
has been described in P. falciparum-treated patients [14,15].
Increasing evidence of a lower P. vivax susceptibility to
CQ in malaria-endemic areas [16] includes the state of
Amazonas [17] and is believed to be associated with malar-
ia’s clinical severity [18].
Molecular markers associated with CQ resistance are non-
synonymous mutations in the drug/metabolite transporter
gene pfcrt (C72S, K76T) and in the multidrug resistance pro-
tein 1 gene pfmdr1 (N86Y; Y184F; S1034C; N1042D;
D1246Y), described in P. falciparum [19-21]. One mutation
of the multidrug resistance gene 1 (Y976F) of P. vivax is also
associated with parasite susceptibility to CQ [8]. A non-
synonymous mutation of the pvdhps gene at codon 382
(S382C) was recently associated with in vitro susceptibility to
CQ [18]. The present study aimed to examine the phenotypic
and genotypic chemoresistance profile of P. falciparum and
P. vivax to commonly used anti-malarial drugs in a Brazilian
malaria-endemic area in the Amazon Region.
Methods
Subjects
All isolates were collected between August 2012 and
March 2013 from patients recruited at the Centre ofMalaria Control (CEPEM) in the city of Porto Velho,
state of Rondônia, in the Brazilian Western Amazon,
where P. vivax is highly prevalent. Only patients mono-
infected with either P. falciparum or P. vivax and with
high parasitaemia (between 2,000 and 80,000 parasites/
μl) were recruited. Patients who used any anti-malarial
in the previous month and/or presented severe symp-
toms of malaria were excluded from this work. The
study cohort encompassed 56 patients living in this
highly endemic area which is close to Bolivia (Figure 1).
Forty seven patients were diagnosed with P. vivax and
eight with P. falciparum. In addition, one isolate of an
individual infected with P. falciparum with imported
malaria (from Africa) was also studied. One patient had
mixed malaria (P. vivax and P. falciparum) and was not
included. From each volunteer, a peripheral venous
blood sample (5 ml) was collected by venipuncture in
heparin-containing tubes and immediately used for the
ex vivo drug susceptibility assay using pre-prepared
plates with the diluted anti-malarials, as described below.
DNA was also extracted from peripheral venous blood
in EDTA containing tubes for parasite genomic analysis.
Ethical approval
This study was approved by the Ethics Committee, Centro
de Pesquisas René Rachou-FIOCRUZ (CAAE −03209212.
7.0000.5091). All participants signed a written informed con-
sent before blood collection.
Pre-dosed plates with test and control drugs
CQ, MQ and ART were prepared as 10 μg/mL stock solu-
tion in dimethyl sulphoxide (DMSO) in 96-well plates
(20 μL per well), then diluted two-fold in RPMI, with vari-
able maximum drug concentration according to each pre-
viously determined activity (shown in parentheses), i.e.
CQ (854 nM), MQ (724 nM), ART (738 nM), lyophilized
and stored at 4°C until further use. Each lot of plates was
assayed for quality control just before use, based on the
profile response to CQ to the P. falciparum laboratory
strains W2 and 3D7, for CQ-resistance and -sensitivity, re-
spectively. All plates were prepared in our laboratory, in
Belo-Horizonte, transported to the field in dry ice and
kept at minus 70°C until use.
Ex vivo drug susceptibility assay
The drug susceptibility of the malaria parasites, from each
patient, was measured in vitro. For P. falciparum the
method used was described by Rieckmann and Antuñano
[22] and for P. vivax by Renapurkar et al. [23] with modi-
fications [24]. White blood cells were removed by filtra-
tion in a CF 11 cellulose column as described [25].
Immediately before the ex vivo drug susceptibility assays,
packed red blood cells with the parasites (iRBC) were di-
luted for a 2% hematocrit, using either complete medium
Figure 1 Rondônia state, West Amazon.
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falciparum cultures; or the McCoy’s 5A medium plus 20%
AB human serum, with P. vivax samples. The iRBC
(200 μl per well) were distributed in the pre-dosed drug
plate. For the maturation of parasites, rings to schizonts,
the plates were maintained in candle jars at 37°C as de-
scribed [26], at different incubation times (48–72 hours).
The control wells were iRBCs and cultured with drug free
complete medium. The incubation parasite-drug was
stopped when 40% of the ring stages reached the schizont
stage (at least four distinct nuclei per parasite) in theTable 1 Set of primer sequences used to characterize gene po
Gene Codons Primer








pfcrt 72, 76 5′- acagATGGCTCACGTT
5′- TTTTGTAACATCCGAAA
*Annealing temperature.drug-free control wells (n = 6 per plate). Thick blood films
were then made from each well, dried, stained with 5%
Giemsa solution for 30 min, and examined microscopic-
ally. The number of schizonts per 100 asexual stage para-
sites was determined for each drug concentration and
then normalized by comparing with the schizont number
in the drug-free control wells (considered as 100%). The
half-maximal drug inhibitory response (IC50) was esti-
mated by curve fitting using software (OriginLab Corpor-
ation, Northampton, MA, USA) and comparing with
parasite growth in the drug-free controls.lymorphisms by Plasmodium falciparum and P. vivax









TAGG −3′ 55 162
CTCACA -3′
Table 2 Characteristics of the study population with
malaria in the Amazon-Brazil
P. falciparum P. vivax
Number of patients 9 47
Male (age) N = 6 (41 ± 4) N = 37 (37 ± 10)
Female (age) N = 3 (22 ± 3) N = 10 (47 ± 13)
Fever at the time of blood collection 9 42
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Genomic DNA of the parasites was extracted using
QIAamp DNA kit (QIAGEN, Chatsworth, CA, USA) and
then subjected to real time PCR (Applied Biosystems®).
The 18S rRNA gene was chosen as target gene since it
contains both highly conserved and variable regions (at
least five copies of the gene are dispersed on separate
chromosomes of the Plasmodium genome). Each 20 μl re-
action mix contained 2 μl of sample DNA, 10 μl Fas-
tSTART DNA SYBR Green reagent (Roche), 6.5 mM
MgCl2 (final concentration), and 0.5 mM concentrations
of each primer (5′-TAACGAACGAGATCTTAA-3′and
5′-GTTCCTCTAAGAAGCTTT-3′). The PCR conditions
consisted of an initial denaturation at 95°C for 10 min,
followed by amplification for 40 cycles of 10 sec at 95°C,
5 sec at 50°C, and 20 sec at 72°C, with fluorescence acqui-
sition at the end of each extension step. Amplification was
immediately followed by a melt programme, consisting of
2 min at 95°C, 2 min at 68°C, and a stepwise temperature
increase of 0.2°C/sec until 90°C, with fluorescence acquisi-
tion at each temperature transition. Fluorescence was ana-
lysed using F1/F2 settings, which improved the detection
of P. falciparum (a cutoff of 35 cycles was used to define
Plasmodium-positive samples). A melting curve analysis
was used to determine the species-specific mean melting
temperature (Tm) based on values determined from the
respective positive controls [27].
Analysis of the crt and mdr1 genes
The pfcrt and mdr1 genes were amplified by PCR with
specific primers for each region (Table 1).The PCR reac-
tions were performed with 3 μl of DNA at 30 ng/μl, mixed
with 6.5 μl of AmpliTaq Gold® PCR Master Mix (Applied
Biosystems, Warrington, UK), 0.5 μl of each primer atTable 3 Overall ex-vivo sensitivity of Brazilian isolates for eac




Chloroquine 178 39 19 9
Artesunate 18 16 1.5 9
Mefloquine 19 11 46 9
*Date from Marfurt et al. [28,29]. **The numbers inside of the parenthesis means: lo10 pmol/μl, on a final volume of 15 μl. The samples
were placed in an Eppendorf Mastercycler® (Hamburg,
Germany) at 94°C for 3 min followed by 35 cycles of
94°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec
and a final extension time at 72°C for 5 min. PCR prod-
ucts were purified using Wizard PCR DNA and Gel
Band Purification Kit (Promega, Madison, USA) following
manufacturer’s protocol and visualized on a silver-stained
6.5% polyacrylamide gel. Purified DNA fragments were
then sequenced using the dideoxy method. Sequence data
were analysed using Sequencher 4.9 software (Gene Codes
Co, Ann Arbor, MI, USA). Sequences were then compared
with those on Plasmo DB gene bank.
Results
Anti-malarial susceptibility
Ex-vivo drug susceptibility was assessed in field isolates
from all 56 patients with a single species infection, either
P. vivax (n = 47) or P. falciparum (n = 9); eight of the lat-
ter were Brazilian isolates freshly collected in the state of
Rondônia, in the Brazilian Western Amazon (Figure 1)
and one was from an individual returning from Angola,
Africa, diagnosed and studied in Belo Horizonte, Brazil,
outside the endemic malaria region.
Adequate parasite growth was achieved in 100% (9/9)
of the P. falciparum and in 68% (32/47) of P. vivax iso-
lates. The characteristics of these isolates are summa-
rized in Table 2. The majority of P. falciparum Brazilian
isolates studied were considered resistant to CQ (IC50 70
nM; range, 0.19 to 223 nM); two susceptible showed
IC50 values of 0.19 and 37 nM; two isolates were consid-
ered resistant to MQ (IC50 of 50 and 63 nM); but, all
isolates were susceptible to ART, since the highest IC50
was 5.8 nM.
Among the P. vivax isolates the results of drug suscepti-
bility to CQ suggests no resistance; the median IC50 was
32 nM; ranging between 3 to 69 nM (Table 3); four iso-
lates (P010, P024, P026, P042) less susceptible to CQ
showed IC50 values higher than 51 nM. In further analysis
32 were examined in the thick smears for the stages of the
parasite blood forms; three patients had approximately
30% of parasites in trophozoite stage, which is considered
a high rate. And, they present high IC50 values to ARTh drug, according to the species tested, and for
t
P. vivax Clinical field isolates
Clinical field isolates
Median IC50 (nM)** n Median IC50 (nM)
70 (0.19-223; 80) 32 (3–69; 64)
1.3 (0.26-5.8; 2.82) 32 21 (0.08-137; 17.4)
21 (1.19-63; 80) 57 (5.0-113; 82)
west IC50, higher IC50 and interquartile range.
Table 4 Anti-malarial activity in vitro in 15 different
human P. vivax isolates for chloroquine (CQ), artesunate
(ART) and mefloquine MQ)
P. vivax isolates % of trophozoites Drugs/IC50 Nm
CQ ART MQ
P006 22 29 15 11
P010 20 61** 11 45
P015 9 13.5 11 6
P022 15 8 11 60
P024 32* 69** 34 113
P025 93* 3.0 28 11
P026 29 51** 137 42
P028 11 6.6 2.8 11
P029 16 34 2.5 5.5
P031 10 15 8.0 8.2
P033 8 23 23 24
P034 17 29 9.6 47
P038 42* 8.5 1.3 2
P037 32* 6.5 9.4 39
P039 88* 6.8 5.2 26
P042 80* 62** 23 15
Mean (±SD) - 23 + 9 32 + 37 32 + 28
*Isolates that presented more than 30% trophozoites. **Isolates that were
considered less sensitive to CQ.
Table 5 Prevalence of molecular markers associated with
P. falciparum resistance to chloroquine
Gene – codon % of mutations Mutations Protein change
PfMDR1
86 0% - -
184 100% TAT > TTT Tyrosine >
Phenylalanine
1034 84% AGT > TGT Serine > cysteine
1042 100% AAT > GAT Asparagine >
Aspartic acid
1246 100% GAT > TAT Aspartic acid >
Tyrosine
PfCRT
72 100% AAA > ACA Lysine > Treonine
76 100% TGT > TCT Cysteine > Serine
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show a strong association between stage-specificity and
drug activities and future studies are needed. The only
African isolate studied was susceptible to the anti-
malarials tested (Table 3).Characterization of the CRT and MDR1 resistance
The parasite profiles of molecular resistance for P. vivax
isolates, using the frequencies of SNPs (Single Nucleotide
Polymorphism) in pvmdr1 codon 976, were examined in
47 samples (Table 1). The product was compared with the
genomic sequence of Salvador I as the reference wild type
found in the Plasmo DB gene bank, and no SNPs were
found. For P. falciparum isolates, frequencies of SNPs in
pfmdr1 codons 86, 184, 1034, 1042 and 1246 are shown in
Table 5. In addition, codons 72 and 76 of pfcrt gene were
also evaluated (Table 5). Mutant alleles at positions 184,
1042 and 1246 on pfmdr1 gene were present in 100% of
the samples. In codon 1034, the frequency of mutation
was 84% and no mutations were found in codon 86.
The pfcrt gene carried SNPs in codons 72 and 76 in all
Brazilian isolates. All isolates presented non-synonymous
mutations (Table 5). The P. falciparum isolate from out-
side Brazil (Angola, Africa) had no SNPs on the pfcrt or
pfmdr1 genes.Discussion
Due to the strong impact of chemo-resistance among the
malaria parasites to most drugs used in the control of the
disease, monitoring the development of resistant phenotypes
and genotyping are priorities wherever endemic malaria is
present. The in vitro methods used to examine anti-malarial
drug sensitivity provide a profile of Plasmodium sensitivity
to a variety of drugs, simultaneously assayed. However, a
lower in vitro sensitivity of a parasite isolate does not imply
drug-resistance in vivo, as other factors can interfere, which
are not determined by in vitro tests. The ex vivo tests pro-
vide an outline of resistant-circulating phenotypes for each
tested drug, provided that an adequate number of patients
are examined in a given area. This was not the case for P.
falciparum in our study: only nine patients were evaluated,
reflecting the reduced transmission of this parasite species
in Brazil [30]. Determining parasite genotype, performed in
parallel, provides further information since mutations in the
pfcrt gene alter the CQ flux and/or reduce drug efficacy
[31]; and provides data for policy makers to decide the best
drug to be prescribed in that area. Ideally, monitoring anti-
malarial chemo-resistance must be continuous since devel-
opment and spreading of resistance are dynamic events,
changing with time and according to human interventions
and other factors such as population migration [32].
The antiplasmodial activity and the molecular profile of
resistance by anti-malarial standards like CQ, ART and
MQ, confirms P. falciparum resistance to CQ only, as
demonstrated in ex-vivo tests against P. vivax and P. fal-
ciparum isolates from patients with naturally acquired
malaria in the state of Rondônia in the Brazilian Western
Amazon, which is substantiated by sequencing of genes
related to resistance to anti-malarial drugs.
There is evidence of P. vivax resistance to CQ in the
state of Amazonas, specifically in the city of Manaus
where an increase in the proportion of P. vivax malaria
parallels an increase of unusual clinical complications
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in vivo test to assess the efficacy of standard supervised
CQ therapy. Among 109 volunteers with P. vivax who
completed the in vivo test, 19 had positive blood smears
within the 28-days follow-up (one on day 14, three on
day 21, and 15 on day 28). All were then required to
undergo an alternative therapy with MQ. In another
study performed by the same group, a lower P. vivax
susceptibility to CQ through the attainment of IC50 by
ELISA assay or using traditional methods [18,34] was
examined; they demonstrated that drug-resistance was
related to the presence of non-synonymous mutation at
pvdhps, pvcrt and pvmdr1.
All P. vivax isolates presently studied in the Brazilian
Western Amazon were sensitive to CQ in ex vivo assays.
Although the threshold of IC50 to define a sample as re-
sistant to CQ is not well established for P. vivax, it has
been proposed that the same threshold used for P. falcip-
arum should be used, with 100 nM threshold of CQ [35].
The IC50 for ART and MQ in P. vivax were also exam-
ined and they were higher when compared with the
values found in P. falciparum. It can be due to differ-
ences in the stage-specific activities of CQ, MQ and AQ
in P. vivax, demonstrated here and by Marfut et al. [28].
It may be interesting to compare the susceptibility of P.
vivax in strains from other regions of the world. This
issue remains to be further studied using strains from
different places.
Only one point mutation for CQ was studied for P. vivax
in the pvmdr1 gene codon 976, but other genes were asso-
ciated with CQ resistance in the Brazilian Amazon, e.g., in
the pvdhps gene in codon 382 (S→C) [18].
Considering that the severity of P. vivax malaria in the
state of Amazonas has been attributed to CQ resistance
and to the increased levels of pvmdr1 and pvcrt-o com-
pared to the levels expressed by parasites from patients
with mild symptoms [36], these genes copy number could
also be evaluated. In addition, the mdr1 copy number is
strongly associated with recrudescence after artesunate-
mefloquine administration, and could be used as a surveil-
lance tool for artesunate-mefloquine resistance, as re-
ported in patients in Cambodia [37,38].
In conclusion, in West Amazon, most P. falciparum iso-
lates were CQ resistance, a data confirmed by parasite geno-
typing. No mutations were found for P. vivax in the region
supporting the lower prevalence of this strain in Brazil.
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